Selected Publications

Fluorescent lung slice
  • The emerging role of exosomal cargo in allograft rejection after lung transplantation. Sharma AK.  J Heart Lung Transplant, 2022 Jan;41(1):34-36
  • Pro-inflammatory IgG1 N-glycan signature correlates with primary graft dysfunction onset in COPD patients. McQuiston A, Scott D, Nord D, Langerude L, Pelaez A, Machuca T, Mehta A, Drake RR, Christie JD, Angel P, Atkinson C. Transpl Immunol. 2022 Apr;71:101491.
  • Nanotherapeutics in transplantation: How do we get to clinical implementation? Plumblee L, Atkinson C, Jaishankar D, Scott E, Tietjen GT, Nadig SN. Am J Transplant. 2022 May;22(5):1293-1298.
  • Set Up for Failure: Pre-Existing Autoantibodies in Lung Transplant. McQuiston A, Emtiazjoo A, Angel P, Machuca T, Christie J, Atkinson C. Front Immunol. 2021 Aug 11;12:711102
  • Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. Zheng C, Sleiman MM, Yang X, He S, Atkinson C, Tomlinson S. J Heart Lung Transplant. 2021 Oct;40(10):1112-1121.
  • A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant ischemia reperfusion injury. Li C, Patel K, Tu Z, Kulik L, Patterson A, Wallace C, Kilkenny J, Cantu E, Sharma AK, Pipkin M, Machuca T, Emtiazjoo A, Goddard M, Holers VM, Nadig S, Christie J, Tomlinson S, and Atkinson C. Am J Transplant, 2021 Jun;21(6):2067-2078
  • In vivo reprogramming of pathogenic lung TNFR2 + cDC2s by IFNβ inhibits HDM-induced asthma. Mansouri S, Gogoi H, Pipkin M, Machuca TN, Emtiazjoo AM, Sharma AK, Jin L. Sci Immunol. 2021 Jul 9;6(61):eabi8472.
  • MicroRNA-206 antagomiR‒enriched extracellular vesicles attenuate lung ischemia‒reperfusion injury through CXCL1 regulation in alveolar epithelial cells. Cai J, Gehrau R, Tu Z, Leroy V, Su G, Shang J, Mas VR, Emtiazjoo A, Pelaez A, Atkinson C, Machuca T, Upchurch GR Jr., Sharma AK. J Heart Lung Transplantation; 2020 Dec;39(12):1476-1490.
  • Emphysema-associated Autoreactive Antibodies Exacerbate Post-LungTransplant Ischemia-Reperfusion Injury. Patel KJ, Cheng Q, Stephenson S, Allen DP, Li C, Kilkenny J, Finnegan R, Montalvo-Calero V, Esckilsen S, Vasu C, Goddard M, Nadig SN, Atkinson C . Am J Respir Cell Mol Biol. 2019 Jun;60(6):678-686. doi: 10.1165/rcmb.2018-0224OC.PMID: 30571141
  • Donor pretreatment with nebulized complement C3a receptor antagonist mitigates brain-death induced immunological injury post-lung transplant. Cheng Q, Patel K, Lei B, Rucker L, Allen DP, Zhu P, Vasu C, Martins PN, Goddard M, Nadig SN, Atkinson C. Am J Transplant. 2018 Oct;18(10):2417-2428. doi: 10.1111/ajt.14717. Epub 2018 Apr 10.PMID: 29504277
  • Increasing circulating sphingosine-1-phosphate attenuates lung injury during ex vivo lung perfusion. Mehaffey JH, Charles, EJ, Narahari AK, Schubert S, Laubach VE, Teman NR, Lynch KR, Kron IL, and Sharma AK. J Thorac Cardiovasc Surg. 2018 Aug;156(2):910-917
  • Mesenchymal stromal cell-derived extracellular vesicles attenuate lung ischemia-reperfusion injury and enhance reconditioning of donor lungs after circulatory death. Stone ML, Zhao Y, Smith JR, Weiss M, Kron IL, Laubach VE, Sharma AK. Respir Res. 2017 Dec 21;18(1):212 [PMCID: PMC5740880]
  • NOX2 activation of NKT cells is blocked by adenosine A2A receptor to inhibit lung reperfusion injury. Sharma AK, LaPar DJ, Stone ML, Zhao Y, Mehta CK, Kron IL, and Laubach VE. Am J Respir Crit Care Med., 2016
  • NADPH oxidase mediates synergistic effects of IL-17 and TNF-α on CXCL1 expression by epithelial cells after lung ischemia-reperfusion. Sharma AK, Mulloy DP, Le LT and Laubach VE. Am J Physiol Lung Cell Mol Physiol, 306(1):L69-79; 2014 [PMCID: PMC3920214]
  • Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation. Juncadella I, Kadl A, Sharma AK, Shim YM, Hochreiter-Hufford A, Borish L, Ravichandran KS. Nature; 2013 Jan 24;493(7433):547-51.
  • Receptor for advanced glycation end products (RAGE) on iNKT cells mediates lung ischemia-reperfusion injury. Sharma AK, LaPar DJ, Stone, ML, Zhao Y, Kron IL, Laubach VE. Am J Transplant,13(9):2255-67, 2013
  • Natural killer T cell-derived IL-17 mediates lung ischemia-reperfusion injury. Sharma AK, LaPar DJ, Zhao Y, Li L, Lau CL, Kron IL, Iwakura Y, Okusa MD, and Laubach VE. Am J Respir Crit Care Med, 183(11):1539-49, 2011
  • Pretreatment strategy with adenosine A2A receptor agonist attenuates reperfusion injury in a preclinical porcine lung transplantation model. LaPar DJ, Laubach VE, Emaminia A, Crosby IK, Sharma AK, Sumner HM, Webb DV, Lau CL, and Kron IL. J Thorac Cardiovasc Surg. 142(4):887-94, 2011.
  • Tissue-derived pro-inflammatory effect of adenosine A2B receptor in lung ischemia-reperfusion injury. Anvari F, Sharma AK, Fernandez LG, Hranjec T, Ravid K, Kron IL and Laubach VE. J Thorac Cardiovasc Surg. 140:871-7, 2010
  • Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. Sharma AK, Laubach VE, Ramos SI, Zhao Y, Linden J, Kron IL, and Yang Z. J Thorac Cardiovasc Surg 139(2):474-482, 2010
  • Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation. Sharma AK, Linden J, Kron IL, Laubach VE. Respir Res. 10:58, 2009